Reply  by Rutledge, Thomas et al.
Future research efforts into HF and depression, as well as heart
disease and psychological states in general, need to measure more
precisely the multiplicity of impacts of depression on an individual
in order to ultimately produce effective treatments. Currently, the
field seems intent on importing the way we treat standard
depression in psychiatry into the way depression should be ap-
proached in cardiology. It is highly unlikely this is going to help
heart patients in the long run, as this would probably neglect the
unique and various specific impacts of depression in heart disease
and vice versa.
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Reply
Dr. Persaud offers several valuable comments concerning our
recent review (1). The relationship between depression and heart
failure (HF) is complex, and we fully agree that furthering our
understanding of how these conditions interrelate will require the
study of important psychosocial factors such as social support and
social isolation in addition to biological mechanisms.
Although our review primarily focused on rates and prospective
significance of depression in HF patients, we would like to use
Dr. Persaud’s comments as a platform to make several specific
suggestions concerning applications to treatment.
First, treating and understanding depression’s effects on HF
patients begins at the stage of symptom recognition, a surprisingly
difficult task. Depression is notoriously underrecognized in medical
patients. The clinical presentations of HF and depression are often
similar, complicating diagnosis and assessment of treatment ben-
efits. Social stigmas against mental health diagnoses can make
patients reluctant to acknowledge depressive symptoms. Depres-
sion may delay treatment-seeking behaviors in some, while in-
creasing health care utilization in others. Depression symptoms
can also vary widely across patients, and the meaning of these
differences for HF is not known. Collectively, these factors
undermine and may even argue against the application of stan-
dardized depression treatments in HF populations.
Second, efficacious treatments for depression are still lacking,
despite the development of state-of-the-art pharmacotherapies. A
substantial patient population does not respond and/or maintains
clinically significant symptoms despite treatment attempts (2), and
responsiveness may itself have prognostic importance (3).
Third, the presence of depression is not random; rather, it is
disproportionately diagnosed among patients who are female,
those suffering more advanced disease, those who are socially
isolated, and those of lower socioeconomic status. These factors
can affect patients’ presenting symptoms, their ability or willing-
ness to participate in treatment, their responsiveness to treatment,
and their susceptibility to relapse.
Our review found the treatment literature for depression in HF
to be poorly developed and methodologically inconsistent. At this
early stage of research—and lacking any conclusive treatment
evidence for survival or event outcomes from the much larger
coronary artery disease literature—we believe it would be impru-
dent to call for clinical trials in HF at this time. Instead, we hope
that our findings and insights from colleagues such as Dr. Persaud
can be used to advance the treatment research in this area for
potential future applications.
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